OWLT Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of 12.58% compared to Owlet, Inc.'s net margin of -12425.36%. Owlet, Inc.'s return on equity of -- beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Owlet, Inc. has a consensus price target of $14.88, signalling downside risk potential of -4.22%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 327.35%. Given that Perspective Therapeutics, Inc. has higher upside potential than Owlet, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Owlet, Inc..

Owlet, Inc. has a beta of 1.734, which suggesting that the stock is 73.364% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

Owlet, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Owlet, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Owlet, Inc. quarterly revenues are $32M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Owlet, Inc.'s net income of $4M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Owlet, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Owlet, Inc. is 2.60x versus 195.28x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nephros, Inc. has a net margin of 12.58% compared to Owlet, Inc.'s net margin of 7.07%. Owlet, Inc.'s return on equity of -- beat Nephros, Inc.'s return on equity of 16.22%.

Owlet, Inc. has a consensus price target of $14.88, signalling downside risk potential of -4.22%. On the other hand Nephros, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 31.85%. Given that Nephros, Inc. has higher upside potential than Owlet, Inc., analysts believe Nephros, Inc. is more attractive than Owlet, Inc..

Owlet, Inc. has a beta of 1.734, which suggesting that the stock is 73.364% more volatile than S&P 500. In comparison Nephros, Inc. has a beta of 1.483, suggesting its more volatile than the S&P 500 by 48.288%.

Owlet, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nephros, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Owlet, Inc. pays -- of its earnings as a dividend. Nephros, Inc. pays out -- of its earnings as a dividend.

Owlet, Inc. quarterly revenues are $32M, which are larger than Nephros, Inc. quarterly revenues of $4.8M. Owlet, Inc.'s net income of $4M is higher than Nephros, Inc.'s net income of $337K. Notably, Owlet, Inc.'s price-to-earnings ratio is -- while Nephros, Inc.'s PE ratio is 35.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Owlet, Inc. is 2.60x versus 2.96x for Nephros, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of 12.58% compared to Owlet, Inc.'s net margin of -862.39%. Owlet, Inc.'s return on equity of -- beat VolitionRX Ltd.'s return on equity of --.

Owlet, Inc. has a consensus price target of $14.88, signalling downside risk potential of -4.22%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 780%. Given that VolitionRX Ltd. has higher upside potential than Owlet, Inc., analysts believe VolitionRX Ltd. is more attractive than Owlet, Inc..

Owlet, Inc. has a beta of 1.734, which suggesting that the stock is 73.364% more volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Owlet, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Owlet, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Owlet, Inc. quarterly revenues are $32M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Owlet, Inc.'s net income of $4M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Owlet, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Owlet, Inc. is 2.60x versus 17.13x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of 12.58% compared to Owlet, Inc.'s net margin of 3.93%. Owlet, Inc.'s return on equity of -- beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Owlet, Inc. has a consensus price target of $14.88, signalling downside risk potential of -4.22%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 93.3%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Owlet, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than Owlet, Inc..

Owlet, Inc. has a beta of 1.734, which suggesting that the stock is 73.364% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Owlet, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Owlet, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Owlet, Inc. quarterly revenues are $32M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Owlet, Inc.'s net income of $4M is higher than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Owlet, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 76.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Owlet, Inc. is 2.60x versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.